---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-023758"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2026-05-15T20:07:33+00:00"
generated_at: "2026-05-15T20:13:27.986328+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q1 net loss down 27% YoY; FDA clears LP-300 trial amendments, IND for pediatric CNS cancer

## Summary
- Net loss of $3.3M ($0.30/sh) vs $4.5M ($0.42/sh) in Q1 2025, a 27% reduction.
- R&D expenses fell 47% YoY to $1.7M; cash & marketable securities $6.3M at March 31, plus $4.4M May financing.
- Successful FDA Type C meeting for LP-300 HARMONIC trial; protocol amended to focus on EGFR exon 21 L858R mutation as single-arm study.
- IND cleared for Starlight Therapeutics' STAR-001 pediatric CNS cancer trial (ATRT); Rare Pediatric Disease Designations.
- Launched withZeta.ai commercial AI platform; announced plan to spin it into independent entity.

## SEC filing metadata
- accession: 0001493152-26-023758
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2026-05-15T20:07:33+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/0001493152-26-023758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-023758
- JSON: https://secwatch.observer/filing/0001493152-26-023758.json
- Plain text: https://secwatch.observer/filing/0001493152-26-023758.txt

## Key facts
- Earnings Releases
  Lantern Pharma Inc. reported financial results for the first quarter ended March 31, 2026.
  - Period: the first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 15, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/0001493152-26-023758-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.